vs
Hilltop Holdings Inc.（HTH）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Hilltop Holdings Inc.的季度营收约是Orthofix Medical Inc.的1.4倍（$300.5M vs $219.9M），Hilltop Holdings Inc.净利率更高（13.0% vs -1.0%，领先14.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 0.6%）
Hilltop Holdings Inc.是总部位于美国得克萨斯州达拉斯的金融控股公司，旗下拥有PlainsCapital Bank、PrimeLending与HilltopSecurities三大核心子公司，为客户提供多元金融产品及银行相关服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HTH vs OFIX — 直观对比
营收规模更大
HTH
是对方的1.4倍
$219.9M
净利率更高
HTH
高出14.0%
-1.0%
两年增速更快
OFIX
近两年复合增速
0.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $300.5M | $219.9M |
| 净利润 | $39.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 13.0% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | -12.4% | 92.4% |
| 每股收益（稀释后） | $0.64 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTHOFIX
| Q1 26 | $300.5M | — | ||
| Q4 25 | $329.9M | $219.9M | ||
| Q3 25 | $330.2M | $205.6M | ||
| Q2 25 | $303.3M | $203.1M | ||
| Q1 25 | $318.5M | $193.6M | ||
| Q4 24 | $301.1M | $215.7M | ||
| Q3 24 | $305.5M | $196.6M | ||
| Q2 24 | $297.0M | $198.6M |
净利润HTHOFIX
| Q1 26 | $39.0M | — | ||
| Q4 25 | $41.6M | $-2.2M | ||
| Q3 25 | $45.8M | $-22.8M | ||
| Q2 25 | $36.1M | $-14.1M | ||
| Q1 25 | $42.1M | $-53.1M | ||
| Q4 24 | $35.5M | $-29.1M | ||
| Q3 24 | $29.7M | $-27.4M | ||
| Q2 24 | $20.3M | $-33.4M |
毛利率HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 16.1% | 0.2% | ||
| Q3 25 | 18.4% | -8.3% | ||
| Q2 25 | 16.3% | -7.9% | ||
| Q1 25 | 18.1% | -25.2% | ||
| Q4 24 | 14.7% | -5.3% | ||
| Q3 24 | 13.9% | -9.6% | ||
| Q2 24 | 10.0% | -12.5% |
净利率HTHOFIX
| Q1 26 | 13.0% | — | ||
| Q4 25 | 12.6% | -1.0% | ||
| Q3 25 | 13.9% | -11.1% | ||
| Q2 25 | 11.9% | -6.9% | ||
| Q1 25 | 13.2% | -27.4% | ||
| Q4 24 | 11.8% | -13.5% | ||
| Q3 24 | 9.7% | -13.9% | ||
| Q2 24 | 6.8% | -16.8% |
每股收益（稀释后）HTHOFIX
| Q1 26 | $0.64 | — | ||
| Q4 25 | $0.68 | $-0.05 | ||
| Q3 25 | $0.74 | $-0.57 | ||
| Q2 25 | $0.57 | $-0.36 | ||
| Q1 25 | $0.65 | $-1.35 | ||
| Q4 24 | $0.55 | $-0.76 | ||
| Q3 24 | $0.46 | $-0.71 | ||
| Q2 24 | $0.31 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $990.8M | — |
| 股东权益账面价值 | $2.2B | $450.0M |
| 总资产 | $15.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.46× | — |
8季度趋势，按日历期对齐
现金及短期投资HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务HTHOFIX
| Q1 26 | $990.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益HTHOFIX
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $450.0M | ||
| Q3 25 | $2.2B | $442.5M | ||
| Q2 25 | $2.2B | $458.3M | ||
| Q1 25 | $2.2B | $458.3M | ||
| Q4 24 | $2.2B | $503.1M | ||
| Q3 24 | $2.2B | $525.9M | ||
| Q2 24 | $2.1B | $546.0M |
总资产HTHOFIX
| Q1 26 | $15.7B | — | ||
| Q4 25 | $15.8B | $850.6M | ||
| Q3 25 | $15.6B | $832.6M | ||
| Q2 25 | $15.4B | $837.2M | ||
| Q1 25 | $15.8B | $823.1M | ||
| Q4 24 | $16.3B | $893.3M | ||
| Q3 24 | $15.9B | $867.9M | ||
| Q2 24 | $15.6B | $882.0M |
负债/权益比HTHOFIX
| Q1 26 | 0.46× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-38.7M | $27.7M | ||
| Q3 25 | $273.0M | $12.4M | ||
| Q2 25 | $-234.6M | $11.6M | ||
| Q1 25 | $5.8M | $-18.4M | ||
| Q4 24 | $273.9M | $23.7M | ||
| Q3 24 | $515.6M | $11.7M | ||
| Q2 24 | $-435.3M | $9.0M |
自由现金流HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-55.5M | $16.8M | ||
| Q3 25 | $271.0M | $2.5M | ||
| Q2 25 | $-234.6M | $4.5M | ||
| Q1 25 | $5.0M | $-25.1M | ||
| Q4 24 | $266.8M | $15.2M | ||
| Q3 24 | $513.8M | $6.3M | ||
| Q2 24 | $-437.3M | $-360.0K |
自由现金流率HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | -16.8% | 7.6% | ||
| Q3 25 | 82.1% | 1.2% | ||
| Q2 25 | -77.4% | 2.2% | ||
| Q1 25 | 1.6% | -13.0% | ||
| Q4 24 | 88.6% | 7.0% | ||
| Q3 24 | 168.2% | 3.2% | ||
| Q2 24 | -147.2% | -0.2% |
资本支出强度HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | 4.9% | ||
| Q3 25 | 0.6% | 4.8% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.3% | 3.5% | ||
| Q4 24 | 2.4% | 4.0% | ||
| Q3 24 | 0.6% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% |
现金转化率HTHOFIX
| Q1 26 | — | — | ||
| Q4 25 | -0.93× | — | ||
| Q3 25 | 5.96× | — | ||
| Q2 25 | -6.50× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 7.71× | — | ||
| Q3 24 | 17.36× | — | ||
| Q2 24 | -21.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
